Affordable Access

deepdyve-link
Publisher Website

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline.

Authors
  • Journath, Gunilla1
  • Hambraeus, Kristina2
  • Hagström, Emil3
  • Pettersson, Billie4
  • Löthgren, Mickael5
  • 1 Cardiology unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. [email protected] , (Sweden)
  • 2 Department of Cardiology, Falun Hospital, Falun, Sweden. , (Sweden)
  • 3 Uppsala Clinical Research Center, and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. , (Sweden)
  • 4 Amgen Inc, Thousand Oaks, California, USA.
  • 5 Amgen (Europe) GmbH, Zug, Switzerland. , (Switzerland)
Type
Published Article
Journal
BMC Cardiovascular Disorders
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Aug 16, 2017
Volume
17
Issue
1
Pages
224–224
Identifiers
DOI: 10.1186/s12872-017-0659-2
PMID: 28814290
Source
Medline
Keywords
License
Unknown

Abstract

Lowering of LDL cholesterol to achieve target levels according to guidelines for post-MI patients may lead to fewer cardiovascular events and avoidance of event costs.

Report this publication

Statistics

Seen <100 times